Clinical Trials Logo

HIV/HCV Coinfection clinical trials

View clinical trials related to HIV/HCV Coinfection.

Filter by:
  • None
  • Page 1

NCT ID: NCT02762383 Terminated - HIV/HCV Coinfection Clinical Trials

Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)

Start date: March 2005
Phase: Phase 3
Study type: Interventional

This is an uncontrolled, open-label, Phase III trial of peginterferon alfa-2a (Pegasys) in participants coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Participants with HIV/HCV who do not show negative or reduced HCV ribonucleic acid (RNA) after at least 12 weeks of treatment with peginterferon alfa-2a plus ribavirin will receive a low dose of peginterferon alfa-2a for 18 months. The primary objective is to evaluate safety and tolerability. Secondary objectives are to evaluate histological, virological, and biochemical effects.

NCT ID: NCT02102451 Active, not recruiting - HIV Clinical Trials

Control and Elimination Within Australia of Hepatitis C From People Living With HIV

CEASE
Start date: July 2014
Phase:
Study type: Observational

The purpose of this study is to evaluate the feasibility of rapid scale-up of new hepatitis C (HCV) treatments, known as interferon-free Direct Acting Antiviral (DAA) drugs, and impact on the proportion of people with HCV within the HIV-HCV coinfected population of Australia. It is hypothesised that a rapid scale-up of hepatitis C treatment with interferon-free therapies in individuals with HIV-HCV coinfection will assist in controlling HCV infection in this population.